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Abstract 
The utilization of whole exome sequencing (WES) is increasing in the clinical setting. 
WES technology often generates incidental findings (IF), which are defined by the American 
College of Medical Genetics and Genomics (ACMG) as “results of a deliberate search for 
pathogenic or likely pathogenic alterations in genes that are not apparently relevant to a 
diagnostic indication for which the sequencing test was ordered” (2013).  The ACMG has 
recommended identifying mutations in 56 genes when labs conduct WES.  This group of 56 
genes, termed the minimum list, includes mutations associated with 24 medically significant 
conditions.   
This study investigated genetic counselors’ views on disclosure of IF’s from the 
minimum list.  A survey was sent to 3,209 genetic counselors through an e-blast to the 
membership of the National Society of Genetic Counselors; 88 responses were received.  
Approximately 75% of participants indicated they strongly support the expectation that 
patient preferences would be established by the lab prior to testing.  This finding implies that, 
according to our respondents, the responsibility of informed consent should fall primarily on 
the lab rather than the clinician.  This view is in direct contrast to the ACMG 
recommendations, which place the burden of obtaining informed consent on the ordering 
clinician (ACMG Board of Directors, 2013).  We acknowledge that, at this time, labs are not 
capable of obtaining informed consent; they can only document what was obtained by the 
clinician.  
Once results are reported by the lab, 81% of counselors reported feeling an obligation 
to disclose any pathogenic mutations of genes on the ACMG’s minimum list, and 65% would 
disclose even with unknown patient preference.  Although only 27% of respondents received 
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a report containing an IF that they felt was inappropriate to return, 60% of genetic counselors 
feel that there are circumstances in which disclosure is inappropriate.  Additionally, 79% of 
genetic counselors expressed great concern about storing undisclosed IF’s in electronic 
medical records since another clinician may unknowingly disclose unwanted information.   
These scenarios are more likely to surface as WES becomes more common in clinical 
practice. This study suggests the clinical genetics community could benefit from guidelines 
on management of undisclosed incidental findings and from the development of 
infrastructure to support that process. 
Introduction 
The cost of genetic sequencing has continued to decrease, allowing whole exome 
sequencing (WES) to be offered in the clinical setting.  While WES has been used in the 
research setting for many years, it is newer to the clinical field.  One of the hallmarks of 
WES and related techniques is the frequency with which it can produce clinically significant 
genetic information that is unrelated to the condition under investigation (Green, Berg, 
Grody, et al., 2013).  As the cost of sequencing continues to fall and clinical applications 
expand, including its use by various specialties and in a wider variety of circumstances, 
genetics professionals are increasingly likely to encounter incidental findings in the 
laboratory report that pose ethical and logistical challenges.   
In 2013, the ACMG designated a list of genes, termed the minimum list, in which 
they recommended that mutations be sought out during WES/WGS and reported to the 
clinician regardless of age or patient preference.  The minimum list contained 56 genes 
associated with 24 medically significant conditions to be analyzed for pathogenic or likely 
pathogenic mutations when clinical WES was ordered (Green, Berg, Grody, et al., 
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2013).  Most of the genes and variants were chosen due to their association with the more 
common etiologies of monogenic disorders that are medically actionable (ACMG 2013).  
The Working Group focused on disorders for which preventative measures and/or treatments 
are available, and disorders where individuals might be asymptomatic for long periods of 
time. In most cases, only variants that were known to be pathogenic or likely pathogenic 
were chosen to be included in the minimum list (Green, Berg, & Grody, et al., 2013).  The 
majority of the conditions on the minimum list, but not all, have available confirmatory 
testing.   
These recommendations sparked a heated debate amongst researchers, laboratories, 
clinicians, and bioethicists.  Those in support of the recommendations argued that patients 
and families should be informed of any incidental findings on the minimum list based on the 
principle of beneficence (Wolf et al., 2008; Abdul-Karim et al., 2013).  Those opposed 
argued that obtaining patient permission was vital prior to disclosure and that patients should 
be able to opt-out of receiving incidental findings arising from the analysis of the minimum 
list of genes. 
Individuals who disagreed with the ACMG’s recommendations argued that the 
mandatory analysis and reporting of mutations in 56 genes was a violation of patient 
autonomy and shared decision making (Ross, 2013).  A major criticism of the ACMG 
recommendations is that they overrode a patient’s right to opt out, which is a vital component 
of the informed consent process.   In this view, patients were denied the choice for or against 
analysis of the target genes, and their “right not-to-know” was violated when they were 
informed of any pathogenic incidental findings from the minimum list (Vayena, 2013). 
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Ultimately, those in support of this argument claimed that patient permission is essential for 
disclosure of incidental findings; therefore, the default position should be nondisclosure. 
The ACMG stated that clinicians have a duty to prevent harm by cautioning patients 
and their families about specific incidental findings and that, “this principle supersedes 
concerns about autonomy” (ACMG, 2013).  They argued that patients have the right to 
decline sequencing if they feel the risks of possible discovery of incidental findings override 
the potential benefits of sequencing (Green, Berg, & Grody et al., 2013).  Green and 
colleagues argued that selectively opting-out of the minimum list only gives the impression 
of patient autonomy, in that some patients may wish to hear some results but not others 
(Green, Lupski, & Biesecker, 2013).  Opting-out entirely takes away the patient’s decision to 
choose a partial list of results. Essentially, the Working Group suggested that clinicians have 
a fiduciary responsibility to report incidental findings that are medically actionable and have 
available preventative measures and/or treatment. 
At the 2014 ACMG meeting, the Working Group revised their guidelines to suggest 
that patients be given the opportunity to opt-out of the minimum list (ACMG 2014).  The 
group based their decision on feedback from members, including a survey that was 
distributed during the annual 2014 ACMG conference in Nashville, TN (ACMG 2014). 
Within this new framework, the responsibility will fall on the clinician who ordered clinical 
sequencing to explain the opt-out option and the potential benefits/limitations of receiving 
incidental findings during the informed consent process. 
Regardless of the ACMG recommendations, situations will arise where clinicians will 
receive information on incidental findings that they do not wish to or cannot disclose.  These 
situations may include, but are not limited to, the following: when a patient is referred and 
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preferences are unknown, when a patient changes his/her mind between the time WES was 
ordered and the time test results are received, and when a patient is unavailable for post-test 
follow up.  Additionally, situations may occur where the clinician wishes to reveal incidental 
findings at a later date.  For example, a clinician may choose to reveal incidental 
findings later if the testing was performed in a critical or emergency setting where disclosing 
results with long term implications might not be reasonable. 
Pre-test counseling and consent is intended to help avoid these 
circumstances.  During the pre-test counseling and the informed consent process, patients 
should be apprised of the possibility of discovering incidental findings, educated about 
possible implications, and given the opportunity to opt-out of receiving incidental 
findings.  In order to obtain informed consent prior to genomic sequencing, the lab must 
work closely with the ordering clinician to guarantee the masking of information the patient 
does not desire to receive (Green, Berg, Grody, et al., 2013).  When pre-test 
counseling/informed consent is inadequate, circumstances may arise in which the clinician 
feels disclosure is inappropriate.  However, once results are reported by the laboratory, 
genetic counselors may feel a legal responsibility to share the incidental findings with the 
patient, potentially creating tension between the clinician’s ethical and legal responsibilities 
(Erickson, 2014). 
Similar circumstances that may result in non-disclosure after testing occur when 
clinicians outside of genetics order WES.  Patients who have undergone WES in a specialty 
outside of genetics are often referred for genetic counseling for results disclosure and follow-
up.  In these circumstances, a genetic counselor may become responsible for a WES report 
that was referred to them from an outside provider.  In these scenarios, the counselor or other 
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clinician responsible for disclosure may not know what information was presented to the 
patient during the informed consent process, and whether or not patient expectations and 
preferences were communicated to the laboratory.  For example, the referring provider may 
fail to inform the patient that mutations in 56 genes would be sought out, or of what any 
given lab reports as a matter of default.  Additionally, the patient may experience a change of 
heart after testing has been completed.  In each of these cases, the genetic counselor may 
decide not to disclose any incidental finding(s) or to delay disclosure and thus be faced with 
the burden of deciding what to do with the unreported information. 
Further guidance is required related to the use of test results for adult-onset conditions 
in minors. In these situations, the outcome may be clinically relevant but will only affect the 
child during his or her adult life (Van El, 2013).  For example, if a test aimed at unveiling the 
cause of a previously unexplained disease finds that a girl is at risk for hereditary breast and 
ovarian cancer, tough questions arise about how to balance respect for her future autonomy 
without depriving her and her family of what may be vital, life-saving information (Van El, 
2013).   
The ACMG joined with the American Academy of Pediatrics (AAP) to release a 
statement that genetic testing in children should be “driven by the best interests of the child” 
(Committee on Bioethics, 2013) and that adult-onset conditions would not be looked for and 
reported as an incidental finding.  However, the ACMG and AAP also noted that incidental 
findings detected through WES for an ill child may provide clinical importance for the health 
of the parents.  It has been argued that if an incidental finding pertaining to an adult-onset 
disorder can have bearing on the health of the parents or other family members, its disclosure 
may reasonably be viewed as enhancing the autonomy of the child (Vayena, 
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2013).  Additionally, the information may potentially benefit other family members who 
could undergo the consent process for the condition found on WES.  It is common practice in 
genetics to help patients that desire to inform at risk family members to seek genetic 
counseling.  The ACMG considers this act of duty under the principle of beneficence.   
Clinicians may still find themselves conflicted on whether or not to disclose results of 
this nature.  There is the risk of harming patients by disclosing sensitive incidental findings, 
while withholding results may indirectly harm patients by denying them access to potentially 
actionable or meaningful health information.  Navigating between these two harms is a 
current challenge facing genetic counselors and other clinicians (Downing et al. 2012). 
When situations arise where genetic counselors do not wish to disclose information 
about incidental findings immediately, or even at all, the question of what to do with the 
report containing incidental findings is not clear-cut.  Once they have the report in hand, 
some genetic counselors may feel a legal duty to disclose everything that is in it to the 
patient, creating conflict between their ethical and legal duties (Erickson, 2014).  Clayton and 
colleagues addressed the possible risk of medical malpractice created by not disclosing 
incidental findings (Clayton et al., 2012).  They stated that clinicians may face liability in two 
ways: for failing to prevent future disease and/or for failing to report incidental findings to 
other clinicians and patients.  Furthermore, once test results from WES become available in 
the electronic medical record, other providers may access these results and disclose 
incidental findings to the patient regardless of their previously stated preferences (Klitzman 
et al., 2013). 
The ACMG guidelines focus on lab practices, and decisions regarding what goes into 
their report, and do not address how and where incidental findings that are reported but not 
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disclosed should be stored.  In most cases, the results of clinical sequencing would likely be 
entered into the patient’s medical record, raising the potential that another clinician, unaware 
of the patient’s wishes, discloses that unsolicited information to the patient (Erickson, 2014). 
Further exploration is needed regarding the ethical and social implications of generating 
incidental findings in view of questions related to informational privacy (Van El, 2013). 
Currently, there is no universally agreed-upon Protocol for handling undisclosed incidental 
findings. 
This study aimed to investigate the storage and handling of incidental findings from 
the ACMG’s list of 56 medically actionable genes, when they are not reported at the time the 
results are returned.  We evaluated clinical situations where genetic counselors might 
potentially be forced to function as custodians of genetic information following WES, how 
test results and follow-up would be handled in those particular cases, and what would be 
done with test results that reveal a medically significant variant when the patient does not 
want to learn that information. 
Methods 
 The survey was piloted with 4 genetic counselors to assess its content and 
clarity.  Revisions were made to reflect comments and suggestions.  The final survey was 
created using SurveyMonkey (https://surveymonkey.com) and was offered through an e-blast 
administered by the National Society of Genetic Counselors (NSGC).  Eligibility criteria 
included membership in the NSGC and participation in clinical genetics practice in the 
United States or Canada.  The initial email was sent on February 8, 2015 to 3,209 members 
of NSGC.  A reminder email was sent on February 21, 2015, and the survey was closed on 
February 27, 2015.  A total of 88 responses were received.  Informed consent was obtained 
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from all individual participants and responses were anonymous and kept securely.  This study 
was approved by the ANDRUS Institutional Review Board. 
Results 
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Lab Policy 
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Reporting of incidental findings  
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The ACMG has identified a number of incidental findings whose 
return following WES is recommended. If you have done 
informed consent for WES, did you discuss the ACMG 
recommendations and offer patients the opportunity to opt-out?
a) Yes
b) No
c) To an extent
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81.4%
7.1%
11.4%
Do you believe that you have an obligation to disclose any 
incidental finding from the ACMG list that is reported by a 
lab?
a) Yes
b) No
c) Don’t know
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Issues around disclosure  
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Discussion 
Pretest Considerations  
Among respondents, there was a strong expectation that patient preferences regarding 
the disclosure of incidental findings would be established by the laboratory prior to testing. 
Approximately 75% of respondents indicated that they would expect laboratories to solicit 
patient preferences as part of informed consent, at least most or all of the time.  Of those 
responses, 69% indicated that they would expect the laboratory to solicit preferences all of 
the time.  This expectation implies that the responsibility for enforcing informed consent falls 
primarily on the laboratory rather than the clinician.  This reliance on the laboratory may 
become increasingly important as more non-genetic specialists begin to order 
WES.  Consistent with this, 30% of participants reported receiving referrals following WES 
from specialists outside of genetics; 9% indicated they receive these referrals on a regular 
basis.  This further underscores the value and necessity of a comprehensive informed consent 
provided by the laboratory as a part of the ordering process.   
Additionally, our results suggest a strong preference for laboratories with a set policy 
on which incidental findings are returned and honoring patient preferences with regard to 
those findings.  One participant stated, “I will not order from a lab that does not offer the 
family an opt-out option”, highlighting the expectation held by many genetic counselors that 
the lab will take patient preference into account and report accordingly.  In fact, 26% of our 
respondents indicated that if they received an incidental finding on a report that the patient 
did not want, they would request a rewritten report without the incidental finding.  Overall, 
these responses imply that pretest ascertainment of patient preferences, as a part of informed 
consent, is absolutely critical in ordering WES.    
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Tendency to disclose  
        With regard to disclosure, 81% of respondents indicated that they feel an obligation to 
disclose any finding associated with the ACMG minimum list of genes that is reported by the 
lab.  Multiple respondents indicated they felt compelled to disclose any and all findings listed 
on a report.   
“I will disclose anything that is reported, and what is reported is based on what the patients 
consented to in our initial conversation” 
“All reported findings should be disclosed to the patient.” 
The inclination toward disclosure does not seem to be tempered by a concern that patients 
may prefer not to receive the information. This may reflect the earlier reported belief that 
genetic counselors rely on laboratories to adhere to patient preferences obtained at the time of 
consent and report accordingly.  
 Even when patient preferences are unknown, 65% of participants indicated they 
would disclose any incidental finding.  Interestingly, 22% of our participants indicated they 
would disclose an incidental finding that the patient did not want if it was included in the 
report, while 35% reported they do not know what they would do, and only 1% said they 
would definitely not disclose it.  This reluctance is in contrast to the respondents’ emphasis, 
discussed previously, on honoring patient preferences.  The variation suggests a strong 
disinclination to withhold information once it is reported.  Once the information is in the 
hands of the clinician, many may feel that disclosure is the only option.  
The most complicated scenarios present themselves when counselors receive 
unanticipated WES results.  When the ACMG developed their policy statement on WES, 
they acknowledged the possibility that testing may be ordered by specialists outside of 
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genetics but did not address clinical challenges that may arise such as responsibility for 
interpreting and contextualizing results without participation in the ordering process (Green, 
Berg, Grody et al., 2013).  When presented with this circumstance, one participant stated that 
he/she would not disclose but would include the result in the patient record, while another 
participant stated that he/she would consult an ethics board.  In any case, no consensus 
existed among our respondents on the best course of action concerning reported incidental 
findings that are not desired by the patient.  Overall, our data suggests that there are both 
ethical and practical dilemmas associated with incidental findings that are reported, yet 
unwanted. 
Issues around Disclosure 
Approximately 73% of respondents indicated they had not experienced a clinical 
situation in which they received an incidental finding that they did not feel was appropriate to 
return.  However, a larger number of counselors suggested that circumstances are likely to 
arise in which it may not be appropriate to return an incidental finding.  Roughly half of our 
respondents either agreed or weren’t sure that circumstances exist in which disclosure would 
not be appropriate at the time of testing, or even at all. 
Although the ACMG recommendations on incidental findings provide some concrete 
guidance in the reporting of WES, uncertainties remain and continue to arise.  One example 
is the deceased patient; 30% of participants agreed that disclosure is inappropriate in 
circumstances in which the patient has died and the immediate next of kin is 
unresponsive.  There is ambiguity in the research field regarding the handling and 
mechanism of disclosure (or lack thereof) of WES results for deceased individuals 
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(Bredenoord et al., 2011; Chan et al., 2012).  This situation is relatively new in the clinical 
realm, and a protocol regarding disclosure to deceased individuals has yet to be put in place. 
Additionally, 22% of participants agreed that disclosure is inappropriate in pediatric 
cases involving adult-onset conditions.  These responses align with the traditional 
recommendation to defer testing for late-onset conditions until adulthood.  However, given 
the current guidelines, these and other circumstances are likely to arise, in which test results 
are included that many genetic counselors in our study consider inappropriate to disclose.  
Storage and handling of incidental findings 
Nearly all of our participants (93%) reported that they use electronic medical records 
(EMR) to store genetic test results, including those obtained from WES.  By and large, these 
results are discussed with the patient prior to or shortly after being entered into the EMR. 
However, when WES results are not discussed with the patient, only 20% would enter the 
results into the EMR and 44% would keep it in the patient's file.  Interestingly, 36% said they 
would not keep undisclosed findings under any circumstance.  One respondent justified not 
entering the results into the EMR by stating, “under absolutely no circumstances should 
undisclosed genetic test results be available in the EMR where any old provider could happen 
upon them and then blabber on about it to the patient - that sounds like a recipe for disaster”.  
Many participants implied that they are uncomfortable with being gatekeepers of 
genetic information, meaning that they don’t want to be held accountable for negative 
repercussions associated with nondisclosure.  On a scale of 1 to 5, with 1 being ‘not at all 
concerned’ and 5 being ‘extremely concerned’, 75% responded that they were either ‘very 
concerned’ or ‘extremely concerned’ with having undisclosed results in the EMR.  There is a 
high level of discrepancy and discomfort regarding clinicians’ perceived ethical and practical 
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responsibilities regarding the storage of undisclosed incidental findings.  Several participants 
expressed concern that another clinician might access and unknowingly disclose unsolicited 
information.  
“If an incidental finding is [not] reported, I would feel responsible if something happened to 
that patient or family member because I did not disclose the results… I would also feel 
extremely uncomfortable having that information in their medical record and potentially 
having another healthcare provider mentioning it to them on accident. I would rather have 
the difficult conversation with them myself.” 
Practice Implications  
 Results from this study affirm the need for shared perspectives with regard to the 
management of undisclosed incidental findings.  Based on our results, the clinical genetic 
counselors in our study have a strong expectation that the laboratory will provide a 
comprehensive informed consent.  Therefore, laboratory genetic counselors may find this 
information useful when updating the informed consent portion on their test requisition 
forms.  A small percentage of genetic counselors are unaware of laboratory policies with 
respect to incidental findings; laboratory genetic counselors may make use of ordering WES 
as an educational opportunity.  In general, relying on the assumption that the report from the 
lab will reflect patient preferences requires a strong cooperative effort between the clinical 
and lab personnel. 
Study Limitations 
There are a number of limitations to this study.  The relatively small sample of 88 
participants limits the generalizability of results.  The small number of participants likely 
reflects the limited number of genetic counselors ordering WES at the time of the survey. 
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Quite possibly, respondents who had experience ordering WES were more likely to self-
select for participation, creating a smaller though more knowledgeable participant pool. 
Several of our survey questions were potentially hypothetical and might not be viewed as 
reflection of actual decisions in real cases but over half of all counselors responding had first-
hand experience.  We were not able to make generalizations on data obtained from open-
ended responses and, in some cases, responses for individual criteria items addressed 
multiple issues.   
Research Recommendations  
Future studies will be necessary to determine the genetic counselor’s optimal role in 
the management of incidental findings as ACMG recommendations are further revised.  Our 
data suggests that WES is often ordered by specialists outside of genetics.  It would be 
beneficial to gain a better understanding of those specialists’ understanding of the appropriate 
handling of incidental findings.  Furthermore, it would be interesting to investigate their 
compliance with practice guidelines in offering informed consent to their patients.  Lastly, 
further investigation into larger and more comprehensive clinician populations will be 
valuable for the continuing discussion surrounding the management of incidental findings in 
WES. 
Conclusion 
Our study found that the clinical genetic counselors responding to our survey have a 
strong expectation that patient preferences regarding the disclosure of incidental findings 
would be established by the laboratory prior to testing.  This view is in direct contrast to the 
ACMG recommendations, which place the burden of obtaining informed consent on the 
ordering clinician (ACMG Board of Directors, 2013).  We acknowledge that at this time, 
laboratories are not capable of obtaining informed consent; they can only document what was 
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consented to.  When an incidental finding on the minimum list is reported by the lab, most 
genetic counselors feel an obligation to disclose, whether or not preferences are known.  
Even when preferences are known and the patient does not want this information, genetic 
counselors are uncomfortable with not disclosing these results.  
Most genetic counselors in our study indicated they had not experienced a 
circumstance in which they had received an incidental finding that they felt would be 
inappropriate to disclose.  However, many genetic counselors feel that these circumstances 
do exist.   Additionally, there is concern over having undisclosed results in the EMR for fear 
that another provider might accidentally reveal them to the patient. As WES becomes more 
common in clinical practice, these scenarios are more likely to surface. This study suggests 
the clinical genetics community could benefit from guidelines on management of undisclosed 
incidental findings as well as the development of infrastructure to support that process. 
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